Locations:
Search IconSearch
June 12, 2018/Cancer

Robotic Partial Nephrectomy for Tumors that Invade Sinus Fat (Video)

Achieving local cancer control without radical nephrectomy

By Jihad Kaouk, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In this era of robotic surgery, indications for partial nephrectomy (PN) are being widened to more complex renal masses.

In this video, we provide technical hints for achieving local cancer control during transperitoneal robotic PN (RPN) for T3 tumors that invade the sinus fat.

Technique

Our refined robotic technique entails a thorough examination of preoperative imaging and intraoperative renal ultrasound. Excision of the tumor is planned in such a way to shift retraction to the sinus fat. Such retraction allows for delineation of the fat involved with the tumor versus normal sinus fat away from the tumor.

We base our enthusiasm for this technique on a study of masses that underwent RPN at our institution. Of the 1,497 renal masses, 512 were suspected to have sinus fat invasion (RENAL score 3 for nearness to the sinus). Of these, 69 (13.5 percent) had pT3a tumor involving sinus fat at final pathology, representing the analyzed cohort. Twenty-four robotic transperitoneal PN were performed by our refined technique described in this video and 45 PNs were performed by our standard institutional technique.

Overall positive surgical margin (PSM) rate for the analyzed cohort (69 patients) was 11.6 percent. In patients operated on by our standard technique, the PSM rate was higher (0 percent versus 17.8 percent, P = 0.031). We were able to practically eliminate positive margins by refining our technique (P = 0.031). In patients operated on with the revised robotic technique presented on this video, trifecta achievement (no positive margins, no complications and excellent kidney function) was even higher compared to the standard technique (54.2 percent versus 20 percent, P = 0.005).

Advertisement

Differences in PSMs were not reflected in early oncological outcomes. Retrospective analysis and limited follow-up represent study limitations.

Conclusion

With consistent experience in robotic surgery, optimal cancer control can be achieved with this customized robotic approach, especially in cases when tumors involve the renal sinus, which would otherwise require a radical nephrectomy.

Clinical fellow Juan Garisto, MD, and research fellow Riccardo Bertolo, MD, assisted in the production of this video.

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Ad